N/A
N=81
Thumb vs Great Toe Recovery
Residual Neuromuscular Blockade
Bottom Line
View on ClinicalTrials.gov: NCT04312256 ↗Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Onset Time of Muscle Relaxation for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles — 180.0; 180.0 seconds
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- TetraGraph (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Jan 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Onset Time of Muscle Relaxation for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles |
180.0; 180.0 | — |
| PRIMARY Recover Time for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles |
180; 180 | — |
| SECONDARY Onset Time of Reversal Agent Administered for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles |
180.0; 180.0 | — |
| SECONDARY Recover Time of Reversal Agent Administered for Flexor Hallucis Brevis (Great Toe) and Adductor Pollicis (Thumb) Muscles |
180.0; 180.0 | — |
Summary
Researches are comparing the accuracy of measuring muscle relaxation in the thumb versus the great toe.
Eligibility Criteria
Inclusion Criteria
- Age > or = 18 years old
- Patients willing to participate and provide an informed consent
- Patients undergoing an elective surgical procedure that requires use of non-depolarizing NMBA agents administered intraoperatively.
- Patients with planned administration of sugammadex as a neuromuscular blocking reversal agent.
Exclusion Criteria
- Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
- Patients with systemic neuromuscular diseases such as myasthenia gravis
- Patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal impairment or end-stage liver disease.
- Patients having surgery that would involve prepping the arm or leg into the sterile field
Data sourced from ClinicalTrials.gov (NCT04312256). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.